ABVC BioPharma, Inc. Share Price
ABVCABVC BioPharma, Inc. Stock Performance
Open $1.56 | Prev. Close $1.55 | Circuit Range N/A |
Day Range $1.53 - $1.59 | Year Range $0.90 - $5.43 | Volume 16,475 |
Average Traded $1.58 |
ABVC BioPharma, Inc. Share Price Chart
About ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is headquartered in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
ABVC BioPharma, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
29-Jun-26 | $1.53 | $1.55 | +2.64% |
26-Jun-26 | $1.46 | $1.51 | +5.21% |
25-Jun-26 | $1.34 | $1.44 | +7.46% |
24-Jun-26 | $1.34 | $1.34 | +1.13% |
22-Jun-26 | $1.32 | $1.32 | -1.12% |
18-Jun-26 | $1.31 | $1.34 | -2.19% |
17-Jun-26 | $1.39 | $1.37 | +4.98% |